Simonsen L, Viboud C, Elixhauser A, Taylor R J, Kapikian A Z
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
J Infect Dis. 2005 Sep 1;192 Suppl 1:S36-43. doi: 10.1086/431512.
RotaShield, a vaccine intended to prevent severe rotavirus diarrhea, was withdrawn in July 1999, 9 months after it became available in the United States, because of a temporal association with intussusception events that occurred in vaccinated infants. We explore here the effect of age on the risk of intussusception.
We reanalyzed a case-control database of the Centers for Disease Control and Prevention by use of a 21-day window, to define vaccine-associated events. We obtained data on vaccine use from the National Immunization Survey and estimated the age-stratified background incidence of intussusception by use of Healthcare Cost and Utilization Project data. We combined these data to estimate how absolute risk varies with age and to model the projected population-attributable risk associated with 3 different vaccination schedules.
We found that the incidence of intussusception associated with the first dose of vaccine increased with age. Infants > or = 90 days old accounted for 80% of cases of intussusception associated with a first dose but had received only 38% of first doses. Modeling of the recommended schedule of vaccination at ages 2, 4, and 6 months projected 1 intussusception event/11,000-16,000 vaccine recipients; modeling of a 2-dose schedule beginning in the neonatal period projected 1 intussusception event/38,000-59,000 vaccine recipients.
The practice of initiating immunization after age 90 days, which we call "catch-up" vaccination, contributed disproportionately to the occurrence of intussusception associated with the use of RotaShield. A fully implemented 2-dose vaccination schedule begun during the neonatal period would lead to, at most, a 7% increase in the incidence of intussusception above the annual background incidence.
Rotashield是一种旨在预防严重轮状病毒腹泻的疫苗,在美国上市9个月后于1999年7月被撤回,原因是它与接种疫苗的婴儿中发生的肠套叠事件存在时间关联。我们在此探讨年龄对肠套叠风险的影响。
我们使用21天的时间窗重新分析了疾病控制和预防中心的病例对照数据库,以确定与疫苗相关的事件。我们从国家免疫调查中获取了疫苗使用数据,并利用医疗保健成本和利用项目数据估计了按年龄分层的肠套叠背景发病率。我们将这些数据结合起来,以估计绝对风险如何随年龄变化,并对与3种不同疫苗接种计划相关的预计人群归因风险进行建模。
我们发现,与第一剂疫苗相关的肠套叠发病率随年龄增加而上升。90日龄及以上的婴儿占与第一剂疫苗相关的肠套叠病例的80%,但仅接种了38%的第一剂疫苗。对2、4和6月龄推荐接种计划的建模预计,每11,000 - 16,000名疫苗接种者中有1例肠套叠事件;对从新生儿期开始的2剂接种计划的建模预计,每38,000 - 59,000名疫苗接种者中有1例肠套叠事件。
90日龄后开始免疫接种(我们称之为“补种”疫苗)的做法,对与使用Rotashield相关的肠套叠发生的贡献不成比例。在新生儿期开始全面实施的2剂疫苗接种计划最多会使肠套叠发病率比年度背景发病率增加7%。